BACKGROUND: This study sought to identify the maximum tolerated dose (MTD) of AT9283, an inhibitor of Aurora kinases A and B, in patients with relapsed or refractory leukemias. Other endpoints included pharmacokinetics, safety and tolerability, pharmacodynamics, and preliminary evidence of efficacy. PATIENTS AND METHODS: AT9283 was administered as a continuous 72-hour infusion every 21 days. Doses were escalated by a standard 3 + 3 design. After the MTD for the 72-hour infusion was identified, infusion duration was increased incrementally to 96 hours and 120 hours. In total, 48 patients received ≥ 1 cycle of AT9283. Median age was 61 years (range, 22-86 years); 56% were men; 75% were diagnosed with AML; and 89% had received ≥ 3 (up to 16) prior lines of therapy. RESULTS: 324 mg/m(2)/72 h AT9283 was determined to be the MTD. Dose-limiting toxicities (DLTs) were myocardial infarction, hypertension, cardiomyopathy, tumor lysis syndrome, pneumonia, and multiorgan failure. Other AT9283-related toxicities (non-DLT) included myelosuppression, predominantly leukopenia and mucositis. Bone marrow blasts decreased ≥ 38% after AT9283 treatment in approximately one-third of patients with relapsed/refractory AML; however, this effect was transient and no objective responses were achieved, despite evidence of Aurora kinase B inhibition. Two patients with accelerated-phase chronic myeloid leukemia showed evidence of benefit, manifested as a cytogenetic response in 1 case; 1 patient completed 6 cycles of treatment. Exposure to AT9283 was generally dose proportional. CONCLUSION: AT9283 tolerability was strongly dose-dependent, with reversible myelosuppression predominating at lower doses and events such as cardiovascular toxicities manifesting at higher doses. Clinical trials with AT9283 are ongoing in alternative patient populations.
BACKGROUND: This study sought to identify the maximum tolerated dose (MTD) of AT9283, an inhibitor of Aurora kinases A and B, in patients with relapsed or refractory leukemias. Other endpoints included pharmacokinetics, safety and tolerability, pharmacodynamics, and preliminary evidence of efficacy. PATIENTS AND METHODS: AT9283 was administered as a continuous 72-hour infusion every 21 days. Doses were escalated by a standard 3 + 3 design. After the MTD for the 72-hour infusion was identified, infusion duration was increased incrementally to 96 hours and 120 hours. In total, 48 patients received ≥ 1 cycle of AT9283. Median age was 61 years (range, 22-86 years); 56% were men; 75% were diagnosed with AML; and 89% had received ≥ 3 (up to 16) prior lines of therapy. RESULTS: 324 mg/m(2)/72 h AT9283 was determined to be the MTD. Dose-limiting toxicities (DLTs) were myocardial infarction, hypertension, cardiomyopathy, tumor lysis syndrome, pneumonia, and multiorgan failure. Other AT9283-related toxicities (non-DLT) included myelosuppression, predominantly leukopenia and mucositis. Bone marrow blasts decreased ≥ 38% after AT9283 treatment in approximately one-third of patients with relapsed/refractory AML; however, this effect was transient and no objective responses were achieved, despite evidence of Aurora kinase B inhibition. Two patients with accelerated-phase chronic myeloid leukemia showed evidence of benefit, manifested as a cytogenetic response in 1 case; 1 patient completed 6 cycles of treatment. Exposure to AT9283 was generally dose proportional. CONCLUSION:AT9283 tolerability was strongly dose-dependent, with reversible myelosuppression predominating at lower doses and events such as cardiovascular toxicities manifesting at higher doses. Clinical trials with AT9283 are ongoing in alternative patient populations.
Authors: H Katayama; T Ota; F Jisaki; Y Ueda; T Tanaka; S Odashima; F Suzuki; Y Terada; M Tatsuka Journal: J Natl Cancer Inst Date: 1999-07-07 Impact factor: 13.506
Authors: Bob Löwenberg; Petra Muus; Gert Ossenkoppele; Philippe Rousselot; Jean-Yves Cahn; Norbert Ifrah; Giovanni Martinelli; Sergio Amadori; Ellin Berman; Pieter Sonneveld; Mojca Jongen-Lavrencic; Sophie Rigaudeau; Paul Stockman; Alison Goudie; Stefan Faderl; Elias Jabbour; Hagop Kantarjian Journal: Blood Date: 2011-10-05 Impact factor: 22.113
Authors: Todd A Carter; Lisa M Wodicka; Neil P Shah; Anne Marie Velasco; Miles A Fabian; Daniel K Treiber; Zdravko V Milanov; Corey E Atteridge; William H Biggs; Philip T Edeen; Mark Floyd; Julia M Ford; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Shamal A Mehta; Hitesh K Patel; William Pao; Charles L Sawyers; Harold Varmus; Patrick P Zarrinkar; David J Lockhart Journal: Proc Natl Acad Sci U S A Date: 2005-07-26 Impact factor: 11.205
Authors: S A Hartsink-Segers; C M Zwaan; C Exalto; M W J Luijendijk; V S Calvert; E F Petricoin; W E Evans; D Reinhardt; V de Haas; M Hedtjärn; B R Hansen; T Koch; H N Caron; R Pieters; M L Den Boer Journal: Leukemia Date: 2012-09-03 Impact factor: 11.528
Authors: Hagop M Kantarjian; Michael W Schuster; Nitin Jain; Anjali Advani; Elias Jabbour; Erick Gamelin; Erik Rasmussen; Gloria Juan; Abraham Anderson; Vincent F Chow; Gregory Friberg; Florian D Vogl; Mikkael A Sekeres Journal: Am J Hematol Date: 2017-06-05 Impact factor: 10.047
Authors: Janna K Duong; Melanie J Griffin; Darren Hargrave; Josef Vormoor; David Edwards; Alan V Boddy Journal: Br J Clin Pharmacol Date: 2017-03-05 Impact factor: 4.335